Biosency

Key People

• Marie Pirotais - Co-founder and CEO
• Yann Le Guillou - Co-founder

Assessment

Team

Aspect: First-time 10+ yrs
Summary: The leadership team comprises first-time entrepreneurs with over a decade of experience in relevant fields.

Marie Pirotais, with 25 years in R&D and innovation, co-founded Biosency in 2017. Her background in strategy, marketing, and project management, combined with co-founder Yann Le Guillou's expertise, provides a solid foundation for the company's endeavors.

Clinical Need

Aspect: Very Strong
Summary: Biosency addresses a critical need in managing chronic respiratory diseases, a leading cause of mortality worldwide.

Chronic obstructive pulmonary disease (COPD) affects millions globally and is a major cause of death. Biosency's Bora care solution offers remote monitoring to prevent exacerbations, addressing a pressing healthcare need.

Competition

Aspect: Somewhat crowded
Summary: The market has several players offering remote monitoring solutions for respiratory conditions.

Competitors like Equivital, LifeWave Biomedical, and Flosonics Medical offer similar wearable technologies for health monitoring, indicating a moderately crowded market.

Technical Challenge

Aspect: Moderate
Summary: Developing accurate and reliable remote monitoring devices presents moderate technical challenges.

Creating a wearable device like Bora band that accurately measures vital signs such as respiratory rate and blood oxygen saturation requires overcoming technical hurdles related to sensor accuracy, data transmission, and user adherence.

Patent

Aspect: Applied
Summary: Biosency has applied for patents to protect its technology.

While specific patent details are not disclosed, Biosency's focus on developing proprietary technology suggests active efforts in securing intellectual property rights.

Financing

Aspect: Medium
Summary: Biosency has secured significant funding but may require additional capital for expansion.

The company raised 7 million in November 2023 to accelerate development and implement predictive algorithms for chronic respiratory diseases. Plans for a 5 million funding round in 2023 indicate ongoing financial needs for international expansion.

Regulatory

Aspect: 510k/PMA
Summary: Biosency's products have obtained necessary regulatory certifications for market entry.

Bora care is a Class IIa medical device with CE MDR certification, allowing its distribution in European markets. The company is also preparing for FDA clearance, expected by 2025, to enter the U.S. market.

Opportunity Rollup

Odds of Success

3.85

Peak Market Share

5.2

Segment CAGR

3.4%

Market Segment

Anesthesia and Respiratory Devices

Market Sub Segment

Remote Patient Monitoring

Key Takeaway

Biosency's innovative remote monitoring solutions address a critical need in managing chronic respiratory diseases, positioning the company for growth despite a competitive market landscape.